Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PANACEA BIOTECH Mar-19 |
MYLAN Dec-18 |
PANACEA BIOTECH/ MYLAN |
5-Yr Chart Click to enlarge
|
||
High | Rs | 354 | 3,561 | - | |
Low | Rs | 138 | 1,960 | - | |
Sales per share (Unadj.) | Rs | 74.6 | 1,638.8 | - | |
Earnings per share (Unadj.) | Rs | 6.7 | 44.5 | - | |
Cash flow per share (Unadj.) | Rs | 15.5 | 351.3 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Dividend yield (eoy) | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 57.2 | 1,772.8 | - | |
Shares outstanding (eoy) | m | 61.25 | 514.50 | - | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 3.3 | 1.7 | 195.8% | |
Avg P/E ratio | x | 36.8 | 62.0 | 59.3% | |
P/CF ratio (eoy) | x | 15.9 | 7.9 | 201.9% | |
Price / Book Value ratio | x | 4.3 | 1.6 | 276.0% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 15,061 | 1,420,461 | 1.1% | |
No. of employees | `000 | 2.3 | 35.0 | 6.6% | |
Total wages/salary | Rs m | 1,471 | 0 | - | |
Avg. sales/employee | Rs Th | 1,973.6 | 24,089.9 | 8.2% | |
Avg. wages/employee | Rs Th | 635.6 | 0 | - | |
Avg. net profit/employee | Rs Th | 176.8 | 654.1 | 27.0% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 4,567 | 843,147 | 0.5% | |
Other income | Rs m | 45 | 0 | - | |
Total revenues | Rs m | 4,612 | 843,147 | 0.5% | |
Gross profit | Rs m | 2,030 | 218,175 | 0.9% | |
Depreciation | Rs m | 540 | 157,870 | 0.3% | |
Interest | Rs m | 1,048 | 40,552 | 2.6% | |
Profit before tax | Rs m | 486 | 19,752 | 2.5% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 77 | -3,142 | -2.5% | |
Profit after tax | Rs m | 409 | 22,895 | 1.8% | |
Gross profit margin | % | 44.4 | 25.9 | 171.8% | |
Effective tax rate | % | 15.9 | -15.9 | -99.7% | |
Net profit margin | % | 9.0 | 2.7 | 329.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 2,415 | 470,812 | 0.5% | |
Current liabilities | Rs m | 9,077 | 343,274 | 2.6% | |
Net working cap to sales | % | -145.9 | 15.1 | -964.5% | |
Current ratio | x | 0.3 | 1.4 | 19.4% | |
Inventory Days | Days | 65 | 84 | 77.9% | |
Debtors Days | Days | 71 | 93 | 76.0% | |
Net fixed assets | Rs m | 8,333 | 163,557 | 5.1% | |
Share capital | Rs m | 61 | 449 | 13.7% | |
Net worth | Rs m | 3,504 | 912,131 | 0.4% | |
Long term debt | Rs m | 461 | 984,482 | 0.0% | |
Total assets | Rs m | 13,755 | 2,446,689 | 0.6% | |
Interest coverage | x | 1.5 | 1.5 | 98.4% | |
Debt to equity ratio | x | 0.1 | 1.1 | 12.2% | |
Sales to assets ratio | x | 0.3 | 0.3 | 96.3% | |
Return on assets | % | 10.6 | 2.6 | 408.6% | |
Return on equity | % | 11.7 | 2.5 | 465.1% | |
Return on capital | % | 38.7 | 3.2 | 1,217.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,049 | 175,206 | 0.6% | |
From Investments | Rs m | -54 | -90,562 | 0.1% | |
From Financial Activity | Rs m | -1,011 | -81,621 | 1.2% | |
Net Cashflow | Rs m | -20 | 1,452 | -1.4% |
Compare PANACEA BIOTECH With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare PANACEA BIOTECH With: ABBOTT INDIA FDC CADILA HEALTHCARE IPCA LABS ORCHID PHARMA
Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.
Ajit Dayal on how India's vaccine strategy will impact the markets.
Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
In this video, I'll you what I think is the real reason behind yesterday's market crash.
This ignored sector could deliver big short-term profits.
More